Acinetobacter infections are caused by the bacterium Acinetobacter baumannii. The disease has emerged as a major cause of healthcare-associated infections. The virulence of Acinetobacter species is low, but these are capable of causing infection in organ transplants and febrile neutropenia. Most of the Acinetobacter isolates recovered from hospitalized patients, particularly those recovered from respiratory secretions and urine, represent colonization rather than infection. Acinetobacter infections are difficult to treat due to resistance shown by multiple antimicrobial agents, including carbapenems and polymyxins, known as multidrug-resistant (MDR) bacterium. Multidrug-resistant A. baumannii is a rapidly emerging pathogen, causing infections including ventilator-associated pneumonia (VAP), bacteremia, urinary tract infection, central venous catheter-related infection, meningitis and wound infection, especially in the intensive care setting.
The treatment of Acinetobacter infections includes antibiotics carbapenems, polymyxins E and B, sulbactam, piperacillin/tazobactam, tigecycline and aminoglycosides. Some of the drug candidates of Acinetobacter infections pipeline include, ETX2514, NOSO-95400 and LCB10-0200. Some of the companies having a pipeline of Acinetobacter infections are Achaogen Inc., Entasis Therapeutics Inc., Pfizer Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.